LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Ignace Vergote, Antonio González-Martı́n, Keiichi Fujiwara, Elsa Kalbacher, Andrea Bagaméri, Sharad Ghamande, J-Y. Lee, Susana Banerjee, Fernando Cotait Maluf, Domenica Lorusso, Kan Yonemori, Els Van Nieuwenhuysen, L.M. Manso Sànchez, Linn Woelber, Anneke M. Westermann, Allan Covens, E. Whalley, M. Teng, Ibrahima Soumaoro, Brian M. Slomovitz